Patents by Inventor Lucy E. Rasmussen

Lucy E. Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purified human cytomegalovirus protein
    Patent number: 5314800
    Abstract: A purified human CMV virion protein that has a molecular weight of approximately 86,000 daltons by SDS-PAGE and exhibits in vivo. immunizing activity and a murine monoclonal antibody that binds specifically to the protein and exhibits complement-independent human CMV neutralizing activity are described. The antibody is useful for isolating the protein by affinity chromatography and the protein is, in turn, useful for detecting CMV neutralizing antibody in sera and as a vaccine.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: May 24, 1994
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lucy E. Rasmussen, Thomas C. Merigan
  • Purified human cytomegalovirus protein
    Patent number: 5194256
    Abstract: A purified human CMV virion protein that has a molecular weight of approximately 86,000 daltons by SDS-PAGE and exhibits in vivo immunizing activity and a murine monoclonal antibody that binds specifically to the protein and exhibits complement-independent human CMV neutralizing activity are described. The antibody is useful for isolating the protein by affinity chromatography and the protein is, in turn, useful for detecting CMV neutralizing antibody in sera and as a vaccine.
    Type: Grant
    Filed: October 2, 1987
    Date of Patent: March 16, 1993
    Assignee: The Board of Trustees of the Leland Sanford Junior University
    Inventors: Lucy E. Rasmussen, Thomas C. Merigan
  • Purified human cytomegalovirus protein
    Patent number: 4743562
    Abstract: A purified human CMV virion protein that has a molecular weight of approximately 86,000 daltons by SDS-PAGE and exhibits in vivo immunizing activity and a murine monoclonal antibody that binds specifically to the protein and exhibits complement-independent human CMV neutralizing activity are described. The antibody is useful for isolating the protein by affinity chromatography and the protein is, in turn, useful for detecting CMV neutralizing antibody in sera and as a vaccine.
    Type: Grant
    Filed: August 21, 1984
    Date of Patent: May 10, 1988
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lucy E. Rasmussen, Thomas C. Merigan